LEXYAL DIVA FACE PN 40mg/2ml
Medical Compliance: | | Clinical Reference: Sci Rep 2020;10:1-12
Clinical Efficacy & Data
Hydration Metrics
Corneometer evaluations indicate a 35% increase in stratum corneum hydration. Sustained moisture retention observed 16 weeks post-treatment.
Fibroblast Migration
In-vitro testing demonstrates a 68% enhancement in fibroblast migration velocity, accelerating tissue repair and endogenous collagen synthesis.
Cellular Exfoliation
Quantitative analysis shows up to a 27% reduction in dead skin cell accumulation, regulating keratinization processes safely.
Formulation Specifications
Active Component: 40mg highly purified Polynucleotides (PN) extracted from Salmon DNA fragments via advanced bio-engineering.
Packaging Volume: 2.0ml pre-filled, sterile medical (1 unit per package).
Safety Profile: Endotoxin levels strictly maintained at < 0.05 EU/g. Optimal physiological pH (6.8 – 7.5).
Viscosity: Medium viscosity optimized for uniform dermal distribution and sustained absorption.
Clinical Administration Protocol
Injection Technique: Micro-papule or mesotherapy injection grid.
Target Depth: Dermal layer (1.5mm – 2.0mm depth).
Recommended Gauge: 30G or 32G.
Dosage per Point: 0.05ml, spaced 1.0cm apart.
Treatment Cycle: Standard protocol requires 3-4 consecutive sessions executed at 2-4 week intervals.
Medical Disclaimer
Strictly designated for professional cosmetic administration by licensed medical practitioners. Contraindicated for patients presenting active dermatological infections, auto-immune pathology, pregnancy, or lactation. Efficacy timelines are patient-dependent; baseline histological improvements mandate minimum 16-week post-treatment evaluation.

Reviews
There are no reviews yet.